PRESS RELEASE
Uppsala
March 14, 2007

Q-Med AB has signed exclusive distribution agreement with Medy-Tox

Q-Med AB and Medy-Tox Inc. have today signed an agreement for the exclusive distribution of Medy-Tox Botulinum Toxin type A product in Europe, excluding Russia, and non-exclusive distribution of the product in Japan.

The contract covers all doses and the indications the product may be used for.
Currently sold under the trade name Neuronox®, the product may under this contract be marketed under a new name in Europe.

The contract is an extension of the development and commercialisation agreement Q-Med AB and Medy-Tox, a South Korean biopharmaceutical company, signed on February 9, 2007 for collaborative development and distribution of new botulinum toxin products.

Medy-Tox Botulinum Toxin type A product is currently approved in South Korea, with approval in several other countries pending and expected during 2007. It is expected that it will take between two and three years before the product obtains EU certification. Present regulatory legislation allows sales in Japan with immediate effect.

Under this contract, Q-Med AB shall pay Medy-Tox a distribution price for the product with no additional upfront or milestone payments. Q-Med shall take responsibility for registration of the product in Europe.

The global market for botulinum toxin products is valued at USD 1.2 billion in 2006. The European market for botulinum toxin is growing rapidly, and it is expected that it will exceed USD 250 million in 2007.

Queries should be addressed to:
Erika Kjellberg Eriksson, CFO, tel: +46 (0) 70 974 90 20
Boris Vujovic, Senior Director Corporate Development and Strategy, tel +44 (0) 780 325 0924

Q-Med AB is a rapidly growing and profitable biotechnology/medical device company. The company develops, produces, markets and sells primarily medical implants. The majority of the products are based on the company's patented technology for the production of stabilized non-animal hyaluronic acid, NASHA™. The product portfolio today contains: RESTYLANE for the filling out of lips and facial wrinkles and for facial contouring, DUROLANE, for the treatment of osteoarthritis of the hip and knee joints, DEFLUX for the treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children, ZUIDEX, for the treatment of stress urinary incontinence in women and SOLESTA, for the treatment of fecal incontinence. Sales are made through the company's own subsidiaries or distributors in over 70 countries. Q-Med today has just over 600 co-workers, with approximately 400 at the company's head office and production facility in Uppsala, Sweden. The Q-Med AB share is listed in the Large Cap segment of the OMX Nordic Stock Exchange in Stockholm.
